Nucana Stock News

The S&P 500 is having a rough start to 2022, down 11.27% year to date. Since Russia invaded Ukraine on Feb. 24, the S&P 500 has fallen an additional 0.78%. Following are lists of sectors via Fidelity

Checkpoint Inhibitor Nivolumab Activity Enhanced by NUC-3373 in vitro

The trading price of NuCana plc (NASDAQ:NCNA) closed lower on Monday, March 07, closing at $0.81, -15.35% lower than its previous close. >> 5 Best Growth Stocks for 2022 << >> 5 Best Growth Stocks for 2022 << Traders who pay close attention to intraday price movement should know that it fluctuated between $0.7789 and … NuCana plc (NASDAQ: NCNA) Drops -15.35 Percent In Recent Session, Why Are You Interested? Read More »

Biotech stocks reversed course in the week ending March 4, as the Ukrainian crisis weighed down on the broader market as well as the sector. The iShares Biotechnology ETF (NASDAQ: IBB ) retreated in four out of five sessions of the week. Clinical trial updates and FDA-related news moved stocks, while earnings news flow tapered off. NuCana plc. (NASDAQ: NCNA ) was among the worst decliners of the week, with the stock reacting to the stalling of the company''s Phase 3 biliary tract cancer study. SAB Biotherapeutics, Inc. (NASDAQ: SABS ) shares also came under pressure after the National Institutes of Health pulled the plug on a Phase study of the company''s SAB-185 in COVID-19 patients. Celayad Oncology SA (NASDAQ: CYAD ) shares plunged after the company said it is pulling the plug on an early-stage biliary tract cancer study. FDA decisions scheduled for the week were mixed, with Amryt Pharma plc (NASDAQ: AMYT ) and Gilead Sciences, Inc. (NASDAQ: GILD ) failing to get their investigational drugs across the finish line.

NuCana PLC Sponsored ADR (NCNA) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analy

Upgrades For Douglas Emmett Inc (NYSE:DEI), Evercore ISI Group upgraded the previous rating of In-Line to Outperform. For the fourth quarter, Douglas Emmett had an EPS of $0.48, compared to year-ago q

Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus NuCana Discontinues Biliary Tract Cancer Study Following Futility Analysis NuCana plc (NASDAQ: NCNA) s

NuCana plc (NASDAQ: NCNA ) will discontinue its NuTide:121 study following a pre-planned futility analysis by the study''s Independent Data Monitoring Committee (IDMC). The NuTide:121 Phase 3 trial assessed Acelarin plus Cisplatin in patients with previously untreated advanced biliary tract cancer. Although a higher objective response rate was observed in the Acelarin plus cisplatin arm, this

Independent Data Monitoring Committee Recommended Study be Discontinued Following Futility Assessment Conducted at First Interim Analysis

EDINBURGH, United Kingdom, Feb. 28, 2022 (GLOBE NEWSWIRE) -- NuCana plc (Nasdaq: NCNA) announced today that Hugh Griffith, Chief Executive Officer, and Don Munoz, Chief Financial Officer, will parti

EDINBURGH, United Kingdom, Feb. 28, 2022 (GLOBE NEWSWIRE) -- NuCana plc (Nasdaq: NCNA) announced today that Hugh Griffith, Chief Executive Officer, and Don Munoz, Chief Financial Officer, will participate in two upcoming virtual investor conferences.

EDINBURGH, United Kingdom, Feb. 28, 2022 (GLOBE NEWSWIRE) -- NuCana plc (Nasdaq: NCNA) announced today that Hugh Griffith, Chief Executive Officer, and Don Munoz, Chief Financial Officer, will partici

Enrollment of 644 Evaluable Patients Expected to Enable Second Interim Analysis in the Second Half of 2022

Here is how NuCana PLC Sponsored ADR (NCNA) and OptiNose (OPTN) have performed compared to their sector so far this year.

Here is how NuCana PLC Sponsored ADR (NCNA) and OptiNose (OPTN) have performed compared to their sector so far this year.